Key Highlights

  • PolyNovo appointed Dean Phizacklea and Andrew Price as independent Non-Executive Directors, effective 18 September 2026.
  • Both will stand for election at the 2026 Annual General Meeting.
  • Christine Emmanuel-Donnelly and Dr Robyn Elliott will retire from the Board and not seek re-election at that meeting.

PolyNovo Limited (ASX:PNV), a medical technology company focused on complex wound management, announced on 17 September 2026 the appointment of Dean Phizacklea and Andrew Price as Non-Executive Directors, effective 18 September 2026. The company describes the appointments as part of the Board's ongoing renewal program and as reflecting a review of the skills and experience needed for its next phase of growth.

Backgrounds of the new directors

Mr Phizacklea is Senior Vice President, Global Strategic Marketing at Cochlear and has more than 30 years' experience in the global medical technology sector, spanning commercial leadership, market access, clinical affairs and growth strategy. He previously held senior executive roles at Cochlear and Abbott.

Mr Price has more than 25 years' experience in global Supply chain, manufacturing, quality and regulatory Leadership in medical technology, including over two decades at ResMed in senior roles with responsibility for large-scale Manufacturing operations and global supply networks. He is also a Non-Executive Director of SomnoMed Limited (ASX: SOM), where he sits on the Audit and Risk Committee.

Independence and election

The Board has determined that both new directors are independent. They will stand for election by shareholders at the company's 2026 Annual General Meeting, so their appointments are not yet confirmed by a Shareholder vote.

Retirements

The appointments follow decisions by Christine Emmanuel-Donnelly and Dr Robyn Elliott to retire from the Board and not seek re-election at the 2026 AGM. Dr Elliott served seven years, providing strategic guidance on operations and quality, and was Acting Interim Chief Executive Officer from March to December 2025. Ms Emmanuel-Donnelly served more than six years, chaired the Remuneration Committee and led remuneration reform, and advised the Board on intellectual property, commercialisation and governance.

About PolyNovo

PolyNovo is headquartered in Melbourne, with operations in the United States, the United Kingdom, India, Hong Kong and Singapore and distributor partners in other markets. Its proprietary NovoSorb polymer is used to address unmet needs in wound care. The announcement contains no financial information, guidance or change to the number of directors, and was authorised by the Board.

Board renewal context

The chair says the new directors bring complementary skills: global commercial leadership, market access and growth strategy, and global supply chain, manufacturing, quality and operational excellence. The announcement describes the Board renewal as ongoing. Dr Elliott's tenure included acting as interim chief executive for nine months across 2025, which the company says provided stability during a critical transition period, and Ms Emmanuel-Donnelly led significant remuneration reform.

Process and limits

The announcement does not name new committee roles for the incoming directors, change the total board size or give remuneration terms. It notes both will stand for election at the 2026 AGM, and both retiring directors will leave at that meeting. The company's description emphasises continued Revenue growth and profitability, but no figures are included in this release.